MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/ehjcvp/pvab031

Медицинская библиотека · European heart journal. Cardiovascular pharmacotherapy · 2022

Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial.

Ferreira João Pedro, Collier Timothy, Clark Andrew L, Mamas Mamas A, Rocca Hans-Peter Brunner-La, Heymans Stephane, González Arantxa, Ahmed Fozia Z, Petutschnigg Johannes, Mujaj Blerim, Cuthbert Joe, Rouet Philippe, Pellicori Pierpaolo, Mariottoni Beatrice, Cosmi Franco, Edelmann Frank, Thijs Lutgarde, Staessen Jan A, Hazebroek Mark, Verdonschot Job, Rossignol Patrick, Girerd Nicolas, Cleland John G, Zannad Faiez

СтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

AIMS: Uncontrolled blood pressure (BP) increases the risk of developing heart failure (HF). The effect of spironolactone on BP of patients at risk of developing HF is yet to be determined. To evaluate the effect of spironolactone on the BP of patients at risk for HF and whether renin can predict spironolactone's effect.

METHODS AND

RESULTS

HOMAGE (Heart OMics in Aging) was a prospective multicentre randomized open-label blinded endpoint (PROBE) trial including 527 patients at risk for developing HF randomly assigned to either spironolactone (25-50 mg/day) or usual care alone for a maximum of 9 months. Sitting BP was assessed at baseline, Months 1 and 9 (or last visit). Analysis of covariance (ANCOVA), mixed effects models, and structural modelling equations was used. The median (percentile25-75) age was 73 (69-79) years, 26% were female, and >75% had history of hypertension. Overall, the baseline BP was 142/78 mmHg. Patients with higher BP were older, more likely to have diabetes and less likely to have coronary artery disease, had greater left ventricular mass (LVM), and left atrial volume (LAV). Compared with usual care, by last visit, spironolactone changed SBP by -10.3 (-13.0 to -7.5) mmHg and DBP by -3.2 (-4.8 to -1.7) mmHg (P < 0.001 for both). A higher proportion of patients on spironolactone had controlled BP <130/80 mmHg (36 vs. 26%; P = 0.014). Lower baseline renin levels predicted a greater response to spironolactone (interactionP = 0.041).

CONCLUSION

Spironolactone had a clinically important BP-lowering effect. Spironolactone should be considered for lowering blood pressure in patients who are at risk of developing HF.

Для цитирования: Ferreira João Pedro, Collier Timothy, Clark Andrew L, Mamas Mamas A, Rocca Hans-Peter Brunner-La, Heymans Stephane, González Arantxa, Ahmed Fozia Z, Petutschnigg Johannes, Mujaj Blerim, Cuthbert Joe, Rouet Philippe, Pellicori Pierpaolo, Mariottoni Beatrice, Cosmi Franco, Edelmann Frank, Thijs Lutgarde, Staessen Jan A, Hazebroek Mark, Verdonschot Job, Rossignol Patrick, Girerd Nicolas, Cleland John G, Zannad Faiez. Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial.. European heart journal. Cardiovascular pharmacotherapy. 2022. DOI: 10.1093/ehjcvp/pvab031.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.